Roche announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use, or CHMP, has recommended expansion of the Hemlibra European Union marketing authorization. If approved, Hemlibra would also be indicated for the routine prophylaxis of bleeding episodes in people with hemophilia A without factor VIII inhibitors, who have moderate disease with a severe bleeding phenotype. It is estimated that people with moderate hemophilia A make up 14% of the hemophilia A population, the company noted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on RHHBY:
- CHMP recommends expansion of EU label for Hemlibra to include people with moderate haemophilia A
- Adagene announces clinical trial collaboration with Roche
- Roche announces collaboration with Pfizer to help patients positive for COVID-19
- Roche announces U.S. collaboration with Pfizer to help patients who test positive for COVID-19 navigate risks, symptoms, testing and treatment options
- Genentech presents data on glofitamab, mosunetuzumab potential at ASH 2022